Literature DB >> 30108847

Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M1 and M2.

Regina Messerer1, Clelia Dallanoce2, Carlo Matera2, Sarah Wehle1, Lisa Flammini3, Brian Chirinda4, Andreas Bock5, Matthias Irmen4, Christian Tränkle4, Elisabetta Barocelli3, Michael Decker1, Christoph Sotriffer1, Marco De Amici2, Ulrike Holzgrabe1.   

Abstract

A set of hybrid compounds composed of the fragment of allosteric modulators of the muscarinic receptor, i.e. W84 and naphmethonium, and the well-known AChE inhibitor tacrine on the one hand, and the skeletons of the orthosteric muscarinic agonists, iperoxo and isox, on the other hand, were synthesized. The two molecular moieties were connected via a polymethylene linker of varying length. These bipharmacophoric compounds were investigated for inhibition of AChE (from electric eel) and BChE (from equine serum) as well as human ChEs in vitro and compared to previously synthesized dimeric inhibitors. Among the studied hybrids, compound 10-C10, characterized by a 10 carbon alkylene linker connecting tacrine and iperoxo, proved to be the most potent inhibitor with the highest pIC50 values of 9.81 (AChE from electric eel) and 8.75 (BChE from equine serum). Docking experiments with compounds 10-C10, 7b-C10, and 7a-C10 helped to interpret the experimental inhibitory power against AChE, which is affected by the nature of the allosteric molecular moiety, with the tacrine-containing hybrid being much more active than the naphthalimido- and phthalimido-containing analogs. Furthermore, the most active AChE inhibitors were found to have affinity to M1 and M2 muscarinic receptors. Since 10-C10 showed almost no cytotoxicity, it emerged as a promising lead structure for the development of an anti-Alzheimer drug.

Entities:  

Year:  2017        PMID: 30108847      PMCID: PMC6072511          DOI: 10.1039/c7md00149e

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  51 in total

1.  Improved protein-ligand docking using GOLD.

Authors:  Marcel L Verdonk; Jason C Cole; Michael J Hartshorn; Christopher W Murray; Richard D Taylor
Journal:  Proteins       Date:  2003-09-01

2.  Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge.

Authors:  Edwin H Rydberg; Boris Brumshtein; Harry M Greenblatt; Dawn M Wong; David Shaya; Larry D Williams; Paul R Carlier; Yuan-Ping Pang; Israel Silman; Joel L Sussman
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

3.  New and original pKa prediction method using grid molecular interaction fields.

Authors:  Francesca Milletti; Loriano Storchi; Gianluca Sforna; Gabriele Cruciani
Journal:  J Chem Inf Model       Date:  2007-10-02       Impact factor: 4.956

Review 4.  Alzheimer's disease.

Authors:  Clive Ballard; Serge Gauthier; Anne Corbett; Carol Brayne; Dag Aarsland; Emma Jones
Journal:  Lancet       Date:  2011-03-01       Impact factor: 79.321

5.  Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE.

Authors:  H Wang; P R Carlier; W L Ho; D C Wu; N T Lee; C P Li; Y P Pang; Y F Han
Journal:  Neuroreport       Date:  1999-03-17       Impact factor: 1.837

6.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.

Authors:  M Harel; I Schalk; L Ehret-Sabatier; F Bouet; M Goeldner; C Hirth; P H Axelsen; I Silman; J L Sussman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  A structure-based design approach to the development of novel, reversible AChE inhibitors.

Authors:  C Doucet-Personeni; P D Bentley; R J Fletcher; A Kinkaid; G Kryger; B Pirard; A Taylor; R Taylor; J Taylor; R Viner; I Silman; J L Sussman; H M Greenblatt; T Lewis
Journal:  J Med Chem       Date:  2001-09-27       Impact factor: 7.446

8.  Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.

Authors:  Johannes Antony; Kerstin Kellershohn; Marion Mohr-Andrä; Anna Kebig; Stefanie Prilla; Mathias Muth; Eberhard Heller; Teresa Disingrini; Clelia Dallanoce; Simona Bertoni; Jasmin Schrobang; Christian Tränkle; Evi Kostenis; Arthur Christopoulos; Hans-Dieter Höltje; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe; Klaus Mohr
Journal:  FASEB J       Date:  2008-10-08       Impact factor: 5.191

9.  Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity.

Authors:  Carlo Matera; Lisa Flammini; Marta Quadri; Valentina Vivo; Vigilio Ballabeni; Ulrike Holzgrabe; Klaus Mohr; Marco De Amici; Elisabetta Barocelli; Simona Bertoni; Clelia Dallanoce
Journal:  Eur J Med Chem       Date:  2014-01-25       Impact factor: 6.514

10.  Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors.

Authors:  Christian Tränkle; Andreas Dittmann; Uwe Schulz; Oliver Weyand; Stefan Buller; Kirstin Jöhren; Eberhard Heller; Nigel J M Birdsall; Ulrike Holzgrabe; John Ellis; Hans Dieter Höltje; Klaus Mohr
Journal:  Mol Pharmacol       Date:  2005-09-12       Impact factor: 4.436

View more
  2 in total

1.  Novel and Potent Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease from Natural (±)-7,8-Dihydroxy-3-methyl-isochroman-4-one.

Authors:  Xinnan Li; Yilin Jia; Junda Li; Pengfei Zhang; Tiantian Li; Li Lu; Hequan Yao; Jie Liu; Zheying Zhu; Jinyi Xu
Journal:  Molecules       Date:  2022-05-11       Impact factor: 4.927

2.  Chasing ChEs-MAO B Multi-Targeting 4-Aminomethyl-7-Benzyloxy-2H-Chromen-2-ones.

Authors:  Mariagrazia Rullo; Marco Catto; Antonio Carrieri; Modesto de Candia; Cosimo Damiano Altomare; Leonardo Pisani
Journal:  Molecules       Date:  2019-12-09       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.